Acute-phase response after radioiodine treatment in hyperthyroidism

Basit Öğe Kaydı
dc.contributor.authorSari, Oktay
dc.contributor.authorTunc, Recep
dc.contributor.authorKisakol, Gurcan
dc.contributor.authorDostbil, Zeki
dc.contributor.authorSerdengecti, Mustafa
dc.date.accessioned2020-03-26T17:16:58Z
dc.date.available2020-03-26T17:16:58Z
dc.date.issued2007
dc.departmentSelçuk Üniversitesien_US
dc.description.abstractPurpose: Acute-phase response is an innate body defense seen during acute illnesses and involving the increased production of certain blood proteins termed acute-phase proteins. There are limited data about acute-phase response after radioiodine therapy. This study is designed to determine whether acute-phase response changes after radioiodine therapy. Materials and Methods: Twenty-six hyperthyroid patients were included in this study, aged between 25 and 69 years (mean, 47.7 +/- 10.5, 18 females and 8 males). All patients were given radioiodine therapy (8-15 mCi). Leukocyte, hemoglobin, platelet, erythrocyte sedimentation rate, and C-reactive protein (CRP) were measured before radioiodine therapy and after 24 hours, 72 hours, 1 week, 1 month, and 3 months. Free T3, free T4, TSH, thyroglobulin (Tg), antithyroid antibody, and antimicrosomal antibody (AMA) were measured before radioiodine therapy and after 1 and 3 months. Results: Mean CRP levels were 3.74, 3.90, 4.29, 5.71, 3.85, and 5.41 mg/L, respectively. There was a significant difference between the initial and the first-week results. Mean Tg levels were 68.15, 143.90, and 77.00 ng/mL, respectively, with a significant difference between the initial and the first-month and third-month results. Mean AMA levels were 158.80, 178.85, and 636.25 IU/mL, respectively, demonstrating a significant difference between the initial and the third-month and first- and third-month results. Conclusion: We have shown that radioiodine therapy causes an increase in CRP, Tg, and AMA levels. We conclude that radioiodine treatment is a cause of the increase in the CRP, Tg, and AMA levels in hyperthyroid patients.en_US
dc.identifier.doi10.1097/01.ten.0000261469.47551.f5en_US
dc.identifier.endpage91en_US
dc.identifier.issn1051-2144en_US
dc.identifier.issue2en_US
dc.identifier.scopusqualityN/Aen_US
dc.identifier.startpage89en_US
dc.identifier.urihttps://dx.doi.org/10.1097/01.ten.0000261469.47551.f5
dc.identifier.urihttps://hdl.handle.net/20.500.12395/21198
dc.identifier.volume17en_US
dc.identifier.wosWOS:000245655600005en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.language.isoenen_US
dc.publisherLIPPINCOTT WILLIAMS & WILKINSen_US
dc.relation.ispartofENDOCRINOLOGISTen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.selcuk20240510_oaigen_US
dc.subjectC-reactive proteinen_US
dc.subjectthyroglobulinen_US
dc.subjectantimicrosomal antibodyen_US
dc.subjectradioiodine treatmenten_US
dc.subjecthyperthyroidismen_US
dc.titleAcute-phase response after radioiodine treatment in hyperthyroidismen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu